Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Espoo – page 15

385 clinical trials in Espoo, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Espoo at a glance
385
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

385 trials in Espoo

Open in trial search

Metapneumovirus infection

Not yet recruiting

Study on the Effectiveness and Safety of IVX-A12 Vaccine for Preventing Respiratory Infections in Adults Aged 60 and Older

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:IVX-121
  • Sponsor:AstraZeneca AB

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

Dermatitis atopic

Not yet recruiting

Study on Rocatinlimab for Adolescents Aged 12-17 with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Subdural haematoma

Not yet recruiting

Effect of Low‑Dose Dexamethasone on Surgical Re‑operation Rate in Adults with Chronic Subdural Hematoma after Burr‑hole Drainage

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:HUS-yhtymae

Breast cancer+2

Not yet recruiting

Gedatolisib with drug combination versus standard therapy as first‑line treatment for patients with advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celcuity Inc.

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Type 1 diabetes mellitus+1

Not yet recruiting

Dapagliflozin and SC0062 in adults with type 1 diabetes and chronic kidney disease: effect on albuminuria in a Phase 2 randomized trial

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Allogenic stem cell transplantation+1

Not yet recruiting

Levofloxacin prophylaxis to reduce bloodstream infections in patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years
  • Substances:Levofloxacin
  • Sponsor:HUS-yhtymae

End stage renal disease+1

Not yet recruiting

Safety and efficacy of locally administered APAC, heparin sodium and sodium chloride to promote arteriovenous fistula maturation in patients with end‑stage kidney disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Aplagon Oy

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cardiac sarcoidosis+1

Not yet recruiting

Diagnostic PET Study of Al[18F]F-NOTA-folate in Patients with Suspected Cardiac Sarcoidosis or Infective Endocarditis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:AL[18F]F-NOTA-FOLATE
  • Sponsor:Turku University Hospital

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Espoo

What the registry says about research in the country

01 Infectious Disease Prevention

Comprehensive research focusing on vaccine development for multiple respiratory viruses, including studies of new formulations against influenza, RSV, and pneumococcal infections. Clinical trials are evaluating innovative immunization approaches for various age groups.

  • Influenza Vaccines
  • RSV Prevention
  • Pneumococcal Protection

Particular emphasis on protecting vulnerable populations such as infants, toddlers, and adults over 60 years old.

02 Cardiovascular Health

Advanced research in cardiovascular medicine, focusing on preventing stroke in atrial fibrillation patients and developing new treatments for acute myocardial infarction. Studies include innovative drug therapies and preventive measures.

  • Stroke Prevention
  • Heart Attack Management
  • Blood Clot Prevention

Trials are investigating new anticoagulants and emergency interventions for heart conditions.

03 Surgical and Specialized Care

Innovative research in surgical procedures and specialized medical conditions, including studies on frostbite treatment, plastic surgery outcomes, and post-operative care protocols.

  • Surgical Complications
  • Emergency Medicine
  • Post-Operative Care

Focus on improving surgical outcomes and developing better treatment protocols for specialized conditions.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.